CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 36 enrolled
Drug / intervention
Cannabidioldrug
Likely dose
Cannabidiol 600mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05317546
NCT05317546Phase 2Completed
CompareCT.gov

Neurobehavioral Effects of Cannabidiol in Youth Alcohol Use Disorder

Medical University of South Carolina·interventional·Posted Apr 8, 2022·Updated Aug 14, 2025

In Brief

A Phase 2 clinical trial evaluating Cannabidiol for Alcohol Use Disorder. Completed, enrolled 36 participants across 1 site.

Detailed Summary

The goal of this study is to test cannabidiol (CBD) as a potentially effective candidate medication for youth alcohol use disorder (AUD). To accomplish this goal, this study will use a randomized, double-blind, within-subjects crossover design. In counterbalanced order, 50 youth (ages 16-22) will receive 600 mg of CBD or placebo three hours before a neuroimaging and behavioral assessment paradigm. The total amount of time the participant will be in the study is approximately one month.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Use Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedApr 8, 2022
Enrollment StartOct 1, 2022
Primary CompletionJun 25, 2024
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 4.2 years ago

Interventions

Cannabidioldrug

In counterbalanced order, 50 youth (ages 16-22) will receive 600mg of cannabidiol or placebo three hours before a neuroimaging and behavioral assessment paradigm, separated by an approximate 18-day washout period.